YAP1 and metabolic dysfunction-associated steatohepatitis: Administration of verteporfin, an inhibitor of YAP that increases levels of 14-3-3a which sequesters YAP in the cytoplasm and targets it for degradation in the proteasome (Wang et al., 2016), to HFD-fed mice, helps to reduce liver inflammation and mitigate the pathogenesis of NASH (Song et al., 2020).